A Succinct Analysis of Hypertension and its Management Strategies
DOI:
https://doi.org/10.61554/ijnrph.v1i1.2023.24Abstract
Hypertension, which is generally known as high blood pressure, holds the utmost significance as a flexible risk factor for overall population worldwide. It is directly related with an increased risk of cardiac disorders. Unfortunately, under half of the sufferer of high BP don’t know about their condition, and the one who know, they are either untreated or not treated properly. However, successful management of this disease has the potential to crucially reduce the worldwide burden of disease and deaths due to hypertension. The cause of hypertension includes a typical reciprocity of natural and physiopathological factors that influence many structures, in addition to genetic predilection. When patients of hypertension are being evaluated with hypertension, this is important to conduct exact and standard BP measurements, assess their predicted risk other heart related problems, determine if there is any indication of organ damage, identify if there is another reason for hypertension, and consider the simultaneous existence of two diseases like cardiac and renal disease. Healthy life management plays a crucial part in lowering BP and inhibiting the occurrence of hypertension and its associated cardiovascular sequelae. These modifications encompass dietary adjustments, increased physical activity, weight management, and other healthy lifestyle choices. Drug therapy or medication is highly effectual in lowering blood pressure and hold back the adverse cardiovascular outcomes in a large no. of patients.
Downloads
Metrics
Keywords:
Pathophysiological Factors, Genetics, Etiology, Antihypertensive Drugs, Therapy.Downloads
Published
How to Cite
Issue
Section
References
Luft FC Twins in Cardiovascular Genetic Research. Luft FC Twins in Cardiovascular Genetic Research Hypertension. 2001;37:350–6. DOI: https://doi.org/10.1161/01.HYP.37.2.350
Surendran P, CHARGE-Heart Failure Consortium, Drenos F, Young R, Warren H, Cook JP, et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat Genet [Internet]. 2016;48(10):1151–61. Available from: http://dx.doi.org/10.1038/ng.3654 DOI: https://doi.org/10.1038/ng.3654
Ehret GB, Ferreira T, Chasman DI, Jackson AU, Schmidt EM, Johnson T, et al. The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. Nat Genet [Internet]. 2016;48(10):1171–84. Available from: http://dx.doi.org/10.1038/ng.3667 DOI: https://doi.org/10.1038/ng.3667
Liu C, Kraja AT, Smith JA, Brody JA, Franceschini N, Bis JC, et al. Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. Nat Genet [Internet]. 2016;48(10):1162– 70. Available from: http://dx.doi.org/10.1038/ng.3660 DOI: https://doi.org/10.1038/ng.3660
Dominiczak A, Delles C, Padmanabhan S. Genomics and precision medicine for clinicians and scientists in hypertension. Hypertension [Internet]. 2017;69(4):e10–3. Available from: http://dx.doi.org/10.1161/HYPERTENSIONAHA. 116.08252 DOI: https://doi.org/10.1161/HYPERTENSIONAHA.116.08252
Ehret GB. Caulfield MJ Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J. 34:951–61. DOI: https://doi.org/10.1093/eurheartj/ehs455
Maass PG, Aydin A, Luft FC, Schächterle C, Weise A, Stricker S, et al. PDE3A mutations cause autosomal dominant hypertension with brachydactyly. Nat Genet [Internet]. 2015;47(6):647–53. Available from: http://dx.doi.org/10.1038/ng.3302 DOI: https://doi.org/10.1038/ng.3302
Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet [Internet]. 2014;384(9943):591–8. Available from: http://dx.doi.org/10.1016/S0140-6736(14)61212-5 DOI: https://doi.org/10.1016/S0140-6736(14)61212-5
Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA [Internet]. 2017;317(2):165. Available from: http://dx.doi.org/10.1001/jama.2016.19043 DOI: https://doi.org/10.1001/jama.2016.19043
Rapsomaniki E. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1•25 million people. Lancet. 2014;383:1899–911. DOI: https://doi.org/10.1016/S0140-6736(14)60685-1
Hall ME, Hall JE. Pathogenesis of Hypertension. In: Hypertension: A Companion to Braunwald’s Heart Disease. Elsevier; 2018. p. 33– 51. DOI: https://doi.org/10.1016/B978-0-323-42973-3.00005-6
De ML. Vascular Aging and Arterial Stiffness. Arq Bras Cardiol. 2017;109:253–8.
Feng W, Dell. Italia LJ & Sanders PW Novel Paradigms of Salt and Hypertension. J Am Soc Nephrol. 2017;28:1362–9. DOI: https://doi.org/10.1681/ASN.2016080927
Wilck N, Matus MG, Kearney SM, Olesen SW, Forslund K, Bartolomaeus H, et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature [Internet]. 2017;551(7682):585–9. Available from: http://dx.doi.org/10.1038/nature24628 DOI: https://doi.org/10.1038/nature24628
Mallat K, John M, Kendrick C, Braun DJ. The vascular endothelium: A regulator of arterial tone and interface for the immune system. Crit Rev Clin Lab Sci. 2017;54:458–70. DOI: https://doi.org/10.1080/10408363.2017.1394267
Serrano-Ponz M, Rodrigo-Gasqué C, Siles E, Martínez-Lara E, Ochoa-Callejero L, Martínez A. Temporal profiles of blood pressure, circulating nitric oxide, and adrenomedullin as predictors of clinical outcome in acute ischemic stroke patients. Mol Med Rep [Internet]. 2016;13(5):3724–34. Available from: http://dx.doi.org/10.3892/mmr.2016.5001 DOI: https://doi.org/10.3892/mmr.2016.5001
Pijacka W, McBryde FD, Marvar PJ, Lincevicius GS, Abdala APL, Woodward L, et al. Carotid sinus denervation ameliorates renovascular hypertension in adult Wistar rats: Carotid body in renovascular hypertension. J Physiol [Internet]. 2016;594(21):6255–66. Available from: http://dx.doi.org/10.1113/jp272708 DOI: https://doi.org/10.1113/JP272708
De Leeuw PW. Sustained Reduction of Blood Pressure With Baroreceptor Activation TherapyNovelty and Significance. Hypertension. 2017;69:836–43. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.117.09086
Grassi G, Mark A, Esler M. Response by Grassi et al to letter regarding article, “the sympathetic nervous system alterations in human hypertension.” Circ Res [Internet]. 2016;119(3):e35-6. Available from: http://dx.doi.org/10.1161/CIRCRESAHA.116.309 261 DOI: https://doi.org/10.1161/CIRCRESAHA.116.309261
Fujita T Mechanism of Salt-Sensitive Hypertension: Focus on Adrenal and Sympathetic Nervous Systems. J Am Soc Nephrol. 2014;25:1148–55. DOI: https://doi.org/10.1681/ASN.2013121258
Harrison DG. Hypertension: A Companion to Braunwald’s Heart Disease 60–69. Bernstein KE Inflammation and Immunity in Hypertension. 2018;60. DOI: https://doi.org/10.1016/B978-0-323-42973-3.00007-X
Whelton PK. PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary. Hypertension. 2017.
Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health [Internet]. 2017;2(2):e108–20. Available from: http://dx.doi.org/10.1016/s2468-2667(17)30003-8 DOI: https://doi.org/10.1016/S2468-2667(17)30003-8
Börjesson M, Onerup A, Lundqvist S, Dahlöf B. Physical activity and exercise lower blood pressure in individuals with hypertension: narrative review of 27 RCTs. Br J Sports Med [Internet]. 2016;50(6):356–61. Available from: http://dx.doi.org/10.1136/bjsports-2015-095786 DOI: https://doi.org/10.1136/bjsports-2015-095786
MacDonald HV, Johnson BT, Huedo-Medina TB, Livingston J, Forsyth KC, Kraemer WJ, et al. Dynamic resistance training as stand-alone antihypertensive lifestyle therapy: A meta-analysis. J Am Heart Assoc [Internet]. 2016;5(10). Available from: http://dx.doi.org/10.1161/JAHA.116.003231 DOI: https://doi.org/10.1161/JAHA.116.003231
Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, et al. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obes Rev [Internet]. 2016;17(10):1001–11. Available from: http://dx.doi.org/10.1111/obr.12433 DOI: https://doi.org/10.1111/obr.12433
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet [Internet]. 2016;387(10022):957–67. Available from: http://dx.doi.org/10.1016/S0140-6736(15)01225-8 DOI: https://doi.org/10.1016/S0140-6736(15)01225-8
Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects: Antihypertensive and metabolic effects. Hypertension [Internet]. 2015;65(5):1041–6. Available from: http://dx.doi.org/10.1161/HYPERTENSIONAHA. 114.05021 DOI: https://doi.org/10.1161/HYPERTENSIONAHA.114.05021
Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev [Internet]. 2017;1(1):CD002003. Available from: http://dx.doi.org/10.1002/14651858.CD002003.pu b5 DOI: https://doi.org/10.1002/14651858.CD002003.pub5
Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med [Internet]. 2016;374(11):1094. Available from: http://dx.doi.org/10.1056/NEJMc1600827 DOI: https://doi.org/10.1056/NEJMc1600827
Jordan J, Stinkens R, Jax T, Engeli S, Blaak EE, May M, et al. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension: Metabolic benefits of sacubitril/valsartan (LCZ696). Clin Pharmacol Ther [Internet]. 2017;101(2):254–63. Available from: http://dx.doi.org/10.1002/cpt.455 DOI: https://doi.org/10.1002/cpt.455
Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol [Internet]. 2017;5(5):333–40. Available from: http://dx.doi.org/10.1016/S2213-8587(17)30087-6 DOI: https://doi.org/10.1016/S2213-8587(17)30087-6
